Current Report Filing (8-k)
September 20 2021 - 5:29PM
Edgar (US Regulatory)
0001419051
false
2000-09-20
0001419051
2021-09-20
2021-09-20
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): September 20, 2021
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
|
(Exact
Name of Registrant as Specified in its Charter)
|
Nevada
|
|
000-54554
|
|
45-1226465
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification Number)
|
701
Wild Rose Lane
|
Elk
City, Idaho 83525
|
(Address
of Principal Executive Offices and Zip Code)
|
|
(760)
295-7208
|
(Issuer’s
telephone number)
|
|
|
(Former
Name or Former Address, if Changed Since Last Report)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol
|
|
Name
of each exchange on which registered
|
Common
|
|
TSOI
|
|
OTC
|
Item
1.01 Entry into a Material Definitive Agreement.
This
Amended 8-K corrects the mutual mistake made as to the Convertible Note subject to the conversion previously reported on June 18, 2019.
The correct Convertible Note (the “Note”) held by Jadi Cell, LLC, is dated November 29, 2018. Jadi Cell, LLC, exercised their
conversion rights under the Note for $287,909 and converted into common shares of TSOI at 0.003 per share for 95,970,000 common.
Item
9.01 Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
September 19, 2021
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.
|
|
|
|
|
By:
|
/s/
Timothy Dixon
|
|
|
Timothy
Dixon
|
|
Chief
Executive Officer
|
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Sep 2023 to Sep 2024